CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...

Recent advances in AI, including machine learning, natural language processing, and deep learning models, are transforming ...

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has been given an average rating of “Hold” by the fourteen analysts that are currently covering the stock, MarketBeat reports. Two investment ...

Introduction: Histone acetylation modifications can regulate gene transcription and play crucial roles in multiple tumorigeneses processes. YEATS domain proteins are one important type of acetylation ...

Head and neck cancers rank fifth in cancer-related mortality and often begin in the tongue, throat, or neck before metastasizing.

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA ...

CRISPR Therapeutics CRSP reported fourth-quarter 2024 loss of 44 cents per share, narrower than the Zacks Consensus Estimate of a loss of $1.15. In the year-ago period, the company recorded ...

Evercore ISI has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to Outperform, citing multiple upcoming catalysts that could drive the stock higher. The firm is now factoring in CTX320 and CTX310 in ...